The CAPItello-291 Trial: Final Overall Survival Results of Capivasertib and Fulvestrant in HR+/HER2− Advanced Breast Cancer

Professor Hope S. Rugo discusses the final overall survival results from the Phase 3 CAPItello-291 trial, evaluating the efficacy, long-term disease control, and safety of combining the AKT inhibitor capivasertib with fulvestrant for patients with AI-resistant, HR+/HER2− advanced breast cancer.

Immunotherapy in Early-Stage Breast Cancer - Report from ESMO BC 2026

Professor Giampaolo Bianchini discusses the evolving landscape of immunotherapy in early-stage breast cancer, focusing on predictive biomarkers, patient selection, and the integration of checkpoint inhibitors into neoadjuvant and adjuvant treatment settings to improve long-term outcomes.